Ross Jeffrey S
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA.
Drug News Perspect. 2010 Jan-Feb;23(1):82-8. doi: 10.1358/dnp.2010.23.1.1437316.
The integration of diagnostics into the selection, administration, dosing and monitoring of the use of anticancer drugs has continued to impact the pharmaceutical industry with particular emphasis on cancers of the breast, colon and lung. An update is given on the biomarkers for these cancers.
将诊断技术整合到抗癌药物的选择、给药、剂量确定和监测过程中，持续对制药行业产生影响，尤其着重于乳腺癌、结肠癌和肺癌。本文提供了这些癌症生物标志物的最新情况。
